Clinical outcomes and immune benefits of anti-epileptic drug therapy in HIV/AIDS
- Kathy Lee†1,
- Pornpun Vivithanaporn†2, 3,
- Reed A Siemieniuk1,
- Hartmut B Krentz1, 4,
- Ferdinand Maingat2,
- M John Gill1, 4, 5 and
- Christopher Power1, 2, 5Email author
© Lee et al; licensee BioMed Central Ltd. 2010
Received: 12 December 2009
Accepted: 17 June 2010
Published: 17 June 2010
Anti-epileptic drugs (AEDs) are frequently prescribed to persons with HIV/AIDS receiving combination antiretroviral therapy (cART) although the extent of AED use and their interactions with cART are uncertain. Herein, AED usage, associated toxicities and immune consequences were investigated.
HIV replication was analysed in proliferating human T cells during AED exposure. Patients receiving AEDs in a geographically-based HIV care program were assessed using clinical and laboratory variables in addition to assessing AED indication, type, and cumulative exposures.
Valproate suppressed proliferation in vitro of both HIV-infected and uninfected T cells (p < 0.05) but AED exposures did not affect HIV production in vitro. Among 1345 HIV/AIDS persons in active care between 2001 and 2007, 169 individuals were exposed to AEDs for the following indications: peripheral neuropathy/neuropathic pain (60%), seizure/epilepsy (24%), mood disorder (13%) and movement disorder (2%). The most frequently prescribed AEDs were calcium channel blockers (gabapentin/pregabalin), followed by sodium channel blockers (phenytoin, carbamazepine, lamotrigine) and valproate. In a nested cohort of 55 AED-treated patients receiving cART and aviremic, chronic exposure to sodium and calcium channel blocking AEDs was associated with increased CD4+ T cell levels (p < 0.05) with no change in CD8+ T cell levels over 12 months from the beginning of AED therapy.
AEDs were prescribed for multiple indications without major adverse effects in this population but immune status in patients receiving sodium or calcium channel blocking drugs was improved.
Anti-epileptic drugs (AEDs) are frequently used as adjunct therapies for several conditions aside from epilepsy and seizures including movement disorders, mood disorders and neuropathic pain [1, 2]. The individual choice of AED is usually made based on the specific indication and potential drug side-effect profile such as hepatic or renal dysfunction, leukopenia, and the patient's co-morbidities as well as concurrent treatments. Nevertheless, monitoring blood AED levels can reduce the incidence of specific AED side-effects. Co-morbid diseases often complicate the use of AEDs, in large part because of their consequences such as organ failure and/or neuropsychiatric effects [3, 4]. Human immunodeficiency virus (HIV) infection is associated with a higher prevalence of neuropathic pain (25-50%) , seizures/epilepsy (3-6%) [6, 7], and mood disorders  than within the general population and often require AED treatment(s) [9–11]. However, the prescription of AEDs in the context of HIV infection, especially in the acquired immunodeficiency disease syndrome (AIDS) phase, can present substantial clinical challenges, given the accompanying risks of hepatic or renal failure together with the increasingly complex range of antiretroviral therapies prescribed for HIV/AIDS. Indeed, some components of combination antiretroviral therapy (cART) such as protease inhibitors often pose serious risks in terms of drug interactions, occasionally with life threatening consequences in individuals who already have multi-organ diseases [12, 13]. Despite these concerns, AEDs continue to be used widely in HIV/AIDS patients receiving cART, albeit with uncertainty regarding potential adverse consequences. The full spectrum of AED use in HIV-infected patients remains unknown, nor is the risk of adverse effects accompanying AED use. Moreover, clinicians caring for patients who receive both AEDs and concurrent antiretroviral drugs face clinical dilemmas arising from the potential interactions between both classes of drugs. Little is known about the impact AEDs on immunologic and virologic markers during HIV infection although in vitro studies suggest that some AEDs (valproate) might enhance viral replication while the in vivo effects remain less certain .
Given these complex circumstances, the working hypothesis was: as AEDs are frequently prescribed for protracted periods for a variety of conditions in HIV/AIDS patients, AEDs might exert substantial effects on virologic, immunologic and clinical outcomes. Viremic status provides a robust indicator of control of HIV infection, which can be used to monitor potentially adverse effects of other interventions such as AEDs initiation, as assessed in the present studies. Herein, we investigated the extent and impact of AED use among aviremic and viremic persons with HIV/AIDS attending a regional HIV program as well as the in vitro effects of frequently used AEDs on T cell proliferation and HIV replication.
Primary human peripheral blood lymphocytes (PBLs) were purified from healthy HIV seronegative subjects' blood with Histopaque (Sigma) and maintained in RPMI 1640 medium with 15% FBS with phytohemagglutinin-P (PHA-P) stimulation for 3 days, followed by hIL-2 stimulation and/or an anti-hCD3 monoclonal antibody (eBioscience, San Diego, CA) for the duration of the experiment . HIV-1 SF162 stocks were used to infect PBLs at day 3 post-isolation of the cells and then treated with gabapentin, valproate or phenytoin (20, 75 and 15 μg/ml, respectively, Sigma) for the duration of the experiment. T cell proliferation was assessed at days 2 and 4 post-infection by CellTrace™ CFSE Cell Proliferation Kit (Molecular Probes, Eugene, OR) and FACS analyses together with reverse transcriptase activity .
The Southern Alberta Clinic (SAC) is a multidisciplinary, geographically-based clinical program, which provides care to all HIV seropositive patients in southern Alberta, Canada . Participation in this study was voluntary and an informed consent was approved by the University of Calgary Ethics Committee. Clinical and laboratory variables were assessed every three to four months, which included complete blood counts, electrolytes, hepatic and renal function tests, blood CD4+/CD8+ T cell levels, plasma viral loads and serum AED levels, when indicated. The principal objective at SAC of cART treatment is to suppress virus in blood to undetectable levels (≤1.6 log10 copies/ml). SAC has access to all contemporary antiretroviral drugs approved in Canada.
All adult patients receiving AEDs were identified within the clinic database (Jan 01/2001-May 01/2007), an in-house computerized database containing all relevant patient characteristics dating back to 1985, which is updated with each patient visit to the clinic. Clinical aspects, laboratory findings, demographic features and AED usage were analyzed. Liver function tests (LFTs) (alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin) were recorded for every AED-treated patient during AED therapy. The severity of hepatotoxicity was graded based on the guideline of AIDS clinical trial group (ACTG)  and the total number of abnormal LFTs was recorded. Cumulative AED dosing was calculated for all patients; cumulative dose (g) was the summation of the days that patients received AEDs multiplied by the dose and frequency to the date of AED being stopped or to the end of the follow up period (May 01/2008).
AED-treated patients were stratified into two groups based on virologic status: AED-receiving patients were defined as "aviremic" if they had been receiving cART for at least one month with an undetectable plasma viral (aviremic) load (≤ 1.6 log10 copies/ml) prior to the introduction of an AED and remained on the same cART regimen for the full duration of AED exposure/therapy and had no episodic of protracted virologic failure (>2 log10 copies/ml) during the period of concomitant exposure to cART and AED; patients were defined as "viremic" if they had detectable viral loads, because they were unable to maintain sustained adherence to drug therapies or had not received antiretroviral therapy prior to AED treatment. The viral load, CD4+ and CD8+ T cell levels prior to initiating AED therapy (baseline) were compared with corresponding values at 6 and 12 month follow-up visits. Patients were not included in this sub-analysis if they did not have viral loads or CD4+ T cell levels prior to the initiation of AED therapy or received AED therapy less than 6 months.
In vitro data were tested by one-way ANOVA with post-hoc Tukey-Kramer. Demographic and clinical variables were analyzed by the Kruskal-Wallis and Chi-square tests for non-parametric continuous and categorical variables, respectively. The levels of CD4+ and CD8+ T cells were tested by Friedman test for non-parametric repeated measures ANOVA with Dunn's multiple comparisons test as a post hoc analysis. The level of significance was defined as p less than 0.05 for all tests.
Cell culture studies
Demographic and clinical features of AED-exposed persons
Demographic and clinical characteristics of HIV/AIDS patients with antiepileptic drug (AED) exposure.
Median age (IQ range)
Median age at HIV diagnosis (IQ range)
HIV risk factor
Median duration of HIV infection (years) (IQ range)
Median baseline CD4+ T cell (cells/mm3) (IQ range)
Median nadir CD4+ T cell (cells/mm3) (IQ range)
Median baseline CD8+ T cell (cells/mm3) (IQ range)
Median baseline log10 viral load (copies/ml) (IQ range)
Late presenter (%)
AED indication, type and cumulative exposure
Liver function tests and AED toxicity
The potential for metabolic interactions between AEDs and different cART regimens is substantial, particularly in terms of ensuing hepatic dysfunction . To address this issue, the frequency and severity of abnormal laboratory tests was investigated among viremic patients as well as those who were aviremic. Both groups showed a similar profile of abnormalities in liver function tests (LFTs) with no abnormalities in half of patients and one abnormal LFT in one-third of patients (Figure 3D). Of the patients who had ≥3 or more LFT abnormalities 8 out of 9 patients received gabapentin. In addition, 54% of patients with gabapentin use experienced at least one abnormal LFT during AED therapy (Figure 3E). Interestingly, aviremic patients with concurrent use of valproate and stable cART regimens experienced a 3 fold higher risk of LFT abnormalities (Figure 3D). The most frequent abnormal LFT was elevated ALT (36.7%), followed by elevated alkaline phosphatase (16.9%), hyperbilirubinemia (9.6%) and elevated AST (9.0%). Most of abnormal LFTs were mild and were categorized as grade 1 hepatotoxicity in both groups except hyperbilirubinemia (Figure 3E and Additional file 1 Figure S1A-C). Only one-third of patients in both groups were experienced one additional LFT abnormality and approximately 10% of patients displayed two or more additional LFT abnormalities (Additional file 1 Figure S1D). Of overall importance, no events of overt hepatic or virologic failure were identified within these AED-treated patient groups regardless of clinical grouping during the study period. Similarly, other organ failures, hospitalization or death due to AED-mediated adverse effects were not observed in this cohort.
Impact of AED therapy on infection status
The present study provides the first longitudinal analysis of cumulative AED use in patients with serious systemic comorbidities and at high risk of drug interactions. Indeed, AEDs were prescribed for multiple indications with limited side-effects in this broadly representative regional population of HIV-infected persons. Despite frequent use and high cumulative doses of AEDs, no events of virologic or organ failure, attributable to AED use were recorded. Drugs within all of the AED classes were prescribed herein but sodium and calcium channel blocking AEDs were the most commonly observed with associated benefits in terms of a rise in CD4+ T cell levels over time while valproate was not associated with improvement in systemic immunity. The frequent use (>10%) of AEDs in HIV/AIDS patients also underscored the burden of neuropsychiatric diseases within this patient population yet provides assurance that AEDs can be used safely among patients receiving cART without serious adverse consequences.
Due to the numerous potential interactions between AEDs and cART in terms of hepatic metabolism, neuropsychiatric and renal side-effects, the relative paucity of adverse events herein was encouraging. In fact, minimal changes in AEDs regimens were required, as dictated by measured AED blood levels. In some instances, the AED dosages were increased to compensate for increased metabolism to achieve therapeutic AED blood levels. Although 1/3 of patients exhibited one abnormal LFT, the severities of abnormal LFTs were mild. This relative lack of undesirable interactions might have been due to regular clinical monitoring of patients with repeated AED blood levels when available (valproate, carbamazepine, phenytoin) together with the frequent use of gabapentin/pregabalin, which are excreted renally. Importantly, previous studies suggest that AEDs including gabapentin and lamotrigine were well tolerated when prescribed to patients with HIV/AIDS [11, 25, 26]. Nonetheless, the risk of abnormal LFTs is considerable within this group of patients; several explanations for these abnormalities lie in the demographics of the cohort including the comparatively high risk of hepatitis virus infection, substance abuse and other concomitant medical issues accompanying immune suppression.
In the present study, several patients were receiving valproate; of interest, earlier studies suggested that valproate increased HIV replication in vitro although the mechanism remains uncertain but this effect was thought to enhance clinical clearance of the virus from tissue reservoirs, eventually improving clinical outcomes . However, the present experimental studies indicated that valproate, phenytoin and gabapentin had no effects on viral replication on T cells infected with a CCR5-dependent strain of HIV-1, similar to a previous study . Conversely, valproate suppressed T cell proliferation in vitro regardless of the presence or absence of concomitant HIV infection, suggesting that valproate influenced the ability of T cells to divide efficiently and further analysis on the effects of antiepileptic drugs on T cell subpopulation is of interest. Indeed, valproate has recently been shown to affect proliferation of malignant cells [27, 28] but had no in vivo effects on viral replication or CD4+ T cell levels [22, 29–31]. However, the current studies showed that concurrent use of calcium (gabapentin, pregabalin) and sodium (carbamazepine, phenytoin, lamotrigine) channel blocking drugs with stable cART regimens, which maintained aviremia, exerted a benefit in terms of increased median CD4+ T cell levels in blood over a 12 month period. Several potential explanations underlie this observation including blocking cation channels and thus stabilizing lymphocyte membrane potentials and/or suppressing intracellular death signalling pathways, thereby, preventing leukocyte depletion. Alternatively, the rise in CD4+ T cell levels might reflect greater patient adherence to cART regimens because they are experiencing a better quality of life due to AED usage. Whatever the explanation for this finding, it warrants further investigation because it might provide insight into additive benefits for the treatment of HIV/AIDS.
This report is the first to assess cumulative exposure of multiple AEDs in any population over time. Despite high cumulative doses of different AEDs, our study showed that the use of several AEDs in HIV-infected patients receiving cART was comparatively safe and might be beneficial to immune status. These findings are clinically relevant because AEDs are widely prescribed in HIV-infected patients with various neuropsychiatric syndromes, as well as in the general population. In summary, this is the first analysis of AED use and effects in HIV/AIDS patients closely monitored in a clinical setting, but also raised interesting questions to be explored in the future regarding immune benefits of AEDs and their underlying mechanisms.
AIDS clinical trial group
acquired immune deficiency syndrome
combination antiretroviral therapy
calcium channel blocker
carboxyfluorescein succinimidyl ester
liver function test
human immunodeficiency virus
peripheral blood lymphocyte
Southern Alberta Clinic
sodium channel blocker
The authors thank Leah DeBlock and Krista Nelles for assistance with manuscript preparation and Dr. Donald Gross for helpful discussions. PV holds a fellowship from the Alberta Heritage Foundation for Medical Research (AHFMR). CP holds a Canada Research Chair (CRC) (Tier 1) in Neurological Infection and Immunity and an AHFMR Senior Scholarship. These studies were supported by the Canadian Institutes of Health Research (CIHR).
- Ettinger AB, Argoff CE: Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain. Neurotherapeutics. 2007, 4 (1): 75-83. 10.1016/j.nurt.2006.10.003.View ArticlePubMed
- Rogawski MA, Loscher W: The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nature medicine. 2004, 10 (7): 685-692. 10.1038/nm1074.View ArticlePubMed
- Kennedy GM, Lhatoo SD: CNS adverse events associated with antiepileptic drugs. CNS Drugs. 2008, 22 (9): 739-760. 10.2165/00023210-200822090-00003.View ArticlePubMed
- Asconape JJ: Some common issues in the use of antiepileptic drugs. Semin Neurol. 2002, 22 (1): 27-39. 10.1055/s-2002-33046.View ArticlePubMed
- Verma S, Estanislao L, Simpson D: HIV-associated neuropathic pain: epidemiology, pathophysiology and management. CNS drugs. 2005, 19 (4): 325-334. 10.2165/00023210-200519040-00005.View ArticlePubMed
- Kellinghaus C, Engbring C, Kovac S, Moddel G, Boesebeck F, Fischera M, Anneken K, Klonne K, Reichelt D, Evers S, et al: Frequency of seizures and epilepsy in neurological HIV-infected patients. Seizure. 2008, 17 (1): 27-33. 10.1016/j.seizure.2007.05.017.View ArticlePubMed
- Pascual-Sedano B, Iranzo A, Marti-Fabregas J, Domingo P, Escartin A, Fuster M, Barrio JL, Sambeat MA: Prospective study of new-onset seizures in patients with human immunodeficiency virus infection: etiologic and clinical aspects. Archives of neurology. 1999, 56 (5): 609-612. 10.1001/archneur.56.5.609.View ArticlePubMed
- Cruess DG, Evans DL, Repetto MJ, Gettes D, Douglas SD, Petitto JM: Prevalence, diagnosis, and pharmacological treatment of mood disorders in HIV disease. Biological psychiatry. 2003, 54 (3): 307-316. 10.1016/S0006-3223(03)00318-4.View ArticlePubMed
- Hahn K, Arendt G, Braun JS, von Giesen HJ, Husstedt IW, Maschke M, Straube ME, Schielke E: A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. Journal of neurology. 2004, 251 (10): 1260-1266. 10.1007/s00415-004-0529-6.View ArticlePubMed
- Halman MH, Worth JL, Sanders KM, Renshaw PF, Murray GB: Anticonvulsant use in the treatment of manic syndromes in patients with HIV-1 infection. The Journal of neuropsychiatry and clinical neurosciences. 1993, 5 (4): 430-434.View ArticlePubMed
- Simpson DM, McArthur JC, Olney R, Clifford D, So Y, Ross D, Baird BJ, Barrett P, Hammer AE: Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology. 2003, 60 (9): 1508-1514.View ArticlePubMed
- Romanelli F, Jennings HR, Nath A, Ryan M, Berger J: Therapeutic dilemma: the use of anticonvulsants in HIV-positive individuals. Neurology. 2000, 54 (7): 1404-1407.View ArticlePubMed
- Liedtke MD, Lockhart SM, Rathbun RC: Anticonvulsant and antiretroviral interactions. The Annals of pharmacotherapy. 2004, 38 (3): 482-489. 10.1345/aph.1D309.View ArticlePubMed
- Robinson B, Turchan J, Anderson C, Chauhan A, Nath A: Modulation of human immunodeficiency virus infection by anticonvulsant drugs. Journal of neurovirology. 2006, 12 (1): 1-4. 10.1080/13550280500516278.View ArticlePubMed
- Power C, McArthur JC, Johnson RT, Griffin DE, Glass JD, Dewey R, Chesebro B: Distinct HIV-1 env sequences are associated with neurotropism and neurovirulence. Current topics in microbiology and immunology. 1995, 202: 89-104.PubMed
- Johnston JB, Jiang Y, van Marle G, Mayne MB, Ni W, Holden J, McArthur JC, Power C: Lentivirus infection in the brain induces matrix metalloproteinase expression: role of envelope diversity. Journal of virology. 2000, 74 (16): 7211-7220. 10.1128/JVI.74.16.7211-7220.2000.PubMed CentralView ArticlePubMed
- Pandya R, Krentz HB, Gill MJ, Power C: HIV-related neurological syndromes reduce health-related quality of life. The Canadian journal of neurological sciences. 2005, 32 (2): 201-204.View ArticlePubMed
- Ogedegbe AO, Sulkowski MS: Antiretroviral-associated liver injury. Clinics in liver disease. 2003, 7 (2): 475-499. 10.1016/S1089-3261(03)00023-0.View ArticlePubMed
- Cloyd MW, Lynn WS, Ramsey K, Baron S: Inhibition of human immunodeficiency virus (HIV-1) infection by diphenylhydantoin (dilantin) implicates role of cellular calcium in virus life cycle. Virology. 1989, 173 (2): 581-590. 10.1016/0042-6822(89)90569-2.View ArticlePubMed
- Maggi JD, Halman MH: The effect of divalproex sodium on viral load: a retrospective review of HIV-positive patients with manic syndromes. Canadian journal of psychiatry. 2001, 46 (4): 359-362.PubMed
- Maggi JD, Halman MH: The effect of divalproex sodium on HIV replication in vivo. The Journal of neuropsychiatry and clinical neurosciences. 2007, 19 (3): 326-330.View ArticlePubMed
- Siliciano JD, Lai J, Callender M, Pitt E, Zhang H, Margolick JB, Gallant JE, Cofrancesco J, Moore RD, Gange SJ, et al: Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. The Journal of infectious diseases. 2007, 195 (6): 833-836. 10.1086/511823.View ArticlePubMed
- Romanelli F, Pomeroy C: Concurrent use of antiretrovirals and anticonvulsants in human immunodeficiency virus (HIV) seropositive patients. Current pharmaceutical design. 2003, 9 (18): 1433-1439. 10.2174/1381612033454676.View ArticlePubMed
- Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, et al: Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 2005, 366 (9485): 549-555. 10.1016/S0140-6736(05)67098-5.PubMed CentralView ArticlePubMed
- La Spina I, Porazzi D, Maggiolo F, Bottura P, Suter F: Gabapentin in painful HIV-related neuropathy: a report of 19 patients, preliminary observations. Eur J Neurol. 2001, 8 (1): 71-75. 10.1046/j.1468-1331.2001.00157.x.View ArticlePubMed
- Archin NM, Eron JJ, Palmer S, Hartmann-Duff A, Martinson JA, Wiegand A, Bandarenko N, Schmitz JL, Bosch RJ, Landay AL, et al: Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS (London, England). 2008, 22 (10): 1131-1135.View Article
- Hrzenjak A, Moinfar F, Kremser ML, Strohmeier B, Staber PB, Zatloukal K, Denk H: Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Molecular cancer therapeutics. 2006, 5 (9): 2203-2210. 10.1158/1535-7163.MCT-05-0480.View ArticlePubMed
- Li XN, Shu Q, Su JM, Perlaky L, Blaney SM, Lau CC: Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Molecular cancer therapeutics. 2005, 4 (12): 1912-1922. 10.1158/1535-7163.MCT-05-0184.View ArticlePubMed
- Ances BM, Letendre S, Buzzell M, Marquie-Beck J, Lazaretto D, Marcotte TD, Grant I, Ellis RJ: Valproic acid does not affect markers of human immunodeficiency virus disease progression. Journal of neurovirology. 2006, 12 (5): 403-406. 10.1080/13550280600981695.View ArticlePubMed
- Schifitto G, Peterson DR, Zhong J, Ni H, Cruttenden K, Gaugh M, Gendelman HE, Boska M, Gelbard H: Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology. 2006, 66 (6): 919-921. 10.1212/01.wnl.0000204294.28189.03.View ArticlePubMed
- Sagot-Lerolle N, Lamine A, Chaix ML, Boufassa F, Aboulker JP, Costagliola D, Goujard C, Pallier C, Delfraissy JF, Lambotte O: Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS (London, England). 2008, 22 (10): 1125-1129.View Article
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2377/10/44/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.